NervGen Pharma Corp

Company Profile

NervGen Pharma Corp had its IPO on under the ticker symbol NGENF.

The company operates in the Healthcare sector and Biotechnology industry. NervGen Pharma Corp has a staff strength of 0 employees.

Stock update

Shares of NervGen Pharma Corp opened at $1.47 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.46 - $1.5, and closed at $1.5.

This is a +3.45% increase from the previous day's closing price.

A total volume of 21,317 shares were traded at the close of the day’s session.

In the last one week, shares of NervGen Pharma Corp have slipped by -1.12%.

NervGen Pharma Corp's Key Ratios

NervGen Pharma Corp has a market cap of $89.64 million, indicating a price to book ratio of 5.1262 and a price to sales ratio of 0.

In the last 12-months NervGen Pharma Corp’s revenue was $0 with a gross profit of $0 and an EBITDA of $-21167076. The EBITDA ratio measures NervGen Pharma Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, NervGen Pharma Corp’s operating margin was 0% while its return on assets stood at -87.15% with a return of equity of -216.88%.

In Q2, NervGen Pharma Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

NervGen Pharma Corp’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.23 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into NervGen Pharma Corp’s profitability.

NervGen Pharma Corp stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.6498. Its price to sales ratio in the trailing 12-months stood at 0.

NervGen Pharma Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$17.42 million

Total Liabilities

$9.70 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

NervGen Pharma Corp ended 2024 with $17.42 million in total assets and $0 in total liabilities. Its intangible assets were valued at $17.42 million while shareholder equity stood at $7.56 million.

NervGen Pharma Corp ended 2024 with $0 in deferred long-term liabilities, $9.70 million in other current liabilities, in common stock, $-65242059.00 in retained earnings and $0 in goodwill. Its cash balance stood at $16.08 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.

NervGen Pharma Corp’s total current assets stands at $16.76 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $40108.00 compared to accounts payable of $886759.00 and inventory worth $0.

In 2024, NervGen Pharma Corp's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, NervGen Pharma Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$1.5

52-Week High

$1.75

52-Week Low

$1.1

Analyst Target Price

$

NervGen Pharma Corp stock is currently trading at $1.5 per share. It touched a 52-week high of $1.75 and a 52-week low of $1.75. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $1.33 and 200-day moving average was $1.32 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 2156.2% of the company’s stock are held by insiders while 0.6% are held by institutions.